Comparison of HER2-Zero and HER2-Low in terms of clinicopathological factors and survival in early-stage breast cancer: A Systematic Review and Meta-analysis

Breast cancer (BC) is the most common cancer in women worldwide and the leading cause of cancer mortality in women [1]. BC can be classified into four distinct molecular subtypes according to the expression of human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), and progesterone receptor (PgR), which are advised as reliable references for precise treatment and prognosis estimation [2]. HER2-positive BC accounts for 15% of whole cases. Although HER2 positivity is known as a poor prognostic feature, it has now been transformed into a predictive advantage thanks to improvements in novel targeted therapy agents like monoclonal antibodies, tyrosine kinase inhibitors, and antibody-drug conjugates against the HER2-receptor family [3].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Systematic or Meta-analysis Studies Source Type: research